SupraVision

SupraVision is an innovative preclinical biotech company focused on developing a first-in-class cell therapy for retinal degenerative diseases, with a primary focus on age-related macular degeneration (AMD). Our proprietary cell-based implant can replace the deteriorated retinal epithelial tissue in the eyes of patients and subsequently restore their vision. This addresses a significant unmet need, as there is currently no cure for AMD. With over 67 million patients in the EU and compelling proof-of-concept preclinical data in an AMD rat model, we are well-positioned to advance our therapy toward IND-enabling studies in 2027. Our experienced team is composed of experts in the fields of cell therapy, biomaterials, translational medicines and supported by renowned retinal surgeons. 

SupraVision is committed to providing a safe, effective, and scalable vision-restoration treatment for patients currently limited to symptomatic remedies. In the future, modifications or additions to the implant will allow us to target a wide range of retinal degenerative diseases.